home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 11/16/21

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar's Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

FLORHAM PARK, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in ...
CLRB - Cellectar Biosciences EPS beats by $0.01

Cellectar Biosciences (NASDAQ:CLRB): Q3 GAAP EPS of -$0.10 beats by $0.01. As of September 30, 2021, the company had cash and cash equivalents of $40.3M compared to $57.2M at December 31, 2020. Press Release For further details see: Cellectar Biosciences EPS beats by $0.01

CLRB - Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quar...

CLRB - Cellectar appoints interim chief medical officer

With the departure of John Friend as its chief medical officer, Cellectar Biosciences (NASDAQ:CLRB) has appointed former company consultant Laurence Reilly to the role in an interim capacity. Former CMO, Friend, is stepping down due to personal reasons, but he will serve the company thro...
CLRB - Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies

FLORHAM PARK, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced it is collaborating with BBK Worldwi...

CLRB - Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the completion of the part A portion of a sa...

CLRB - Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will p...
CLRB - Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National ...

CLRB - Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131) Agreement adds second manufacturer and expands Cellectar’s current supply capabilities FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.&#...

CLRB - Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ende...
Previous 10 Next 10